|
| 36526515 | Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction. | J Am Coll Cardiol | 2023 |
| 36221810 | Clonal haematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers. | European Journal of Heart Failure | 2023 |
| 36342789 | Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. | Circulation | 2023 |
| 36082907 | Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality. | Cardiovascular Research | 2023 |
| 36004495 | Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies. | Cardiovascular Research | 2023 |
| 36326604 | Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. | JAMA Cardiol | 2023 |
| 35976430 | Comorbidities complicating heart failure: changes over the last 15Â years. | Clinical Research in Cardiology | 2023 |
| 37940229 | Multiomics Analysis Provides Novel Pathways Related to Progression of Heart Failure. | J Am Coll Cardiol | 2023 |
| 37589740 | Micronutrient deficiencies and new-onset atrial fibrillation in a community-based cohort: data from PREVEND. | Clin Res Cardiol | 2023 |
| 37905371 | Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies. | Eur J Heart Fail | 2023 |
| 38094687 | The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF. | JACC Basic Transl Sci | 2023 |
| 37901944 | [2023 ESC Guidelines for the management of cardiomyopathies]. | | 2023 |
| 37565978 | Penetrance and Prognosis of MYH7 Variant-Associated Cardiomyopathies: Results From a Dutch Multicenter Cohort Study. | | 2023 |
| 37634707 | Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. | J Am Coll Cardiol | 2023 |
| 37632455 | Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. | Circulation | 2023 |
| 37614579 | Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure. | | 2023 |
| 38046028 | Albuminuria and the risk of cancer: the Stockholm CREAtinine Measurements (SCREAM) project. | | 2023 |
| 37955153 | DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters. | | 2023 |
| 37684330 | Relative fat mass and prediction of incident atrial fibrillation, heart failure and coronary artery disease in the general population. | | 2023 |
| 37610398 | Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. | J Am Coll Cardiol | 2023 |
| 37609881 | Pressure Overload-Induced Cardiac Hypertrophy Stimulates Tumor Growth in Tumor-Prone Apc Mice. | | 2023 |
| 37347663 | FIRRM/C1orf112 is synthetic lethal with PICH and mediates RAD51 dynamics. | | 2023 |
| 36592046 | IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF. | JACC Heart Fail | 2023 |
| 37407113 | Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure. | J Am Coll Cardiol | 2023 |
| 37344985 | The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health-economic analysis of the DELIVER trial. | | 2023 |
| 37282824 | Trajectories of renal biomarkers and new-onset heart failure in the general population: Findings from the PREVEND study. | | 2023 |
| 37216272 | Telemonitoring for heart failure: a meta-analysis. | | 2023 |
| 36778260 | Large scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy. | medRxiv | 2023 |
| 36587945 | The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies. | | 2023 |
| 37278928 | Circulating Acylcarnitines Associated with Hypertrophic Cardiomyopathy Severity: an Exploratory Cross-Sectional Study in MYBPC3 Founder Variant Carriers. | | 2023 |
| 37212168 | Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial. | Eur J Heart Fail | 2023 |
| 37211977 | Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials. | Eur J Heart Fail | 2023 |
| 37210608 | Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HF. | Eur J Heart Fail | 2023 |
| 37210081 | A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers. | | 2023 |
| 37208998 | Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial. | JAMA Cardiol | 2023 |
| 36901846 | Galectin-3 and Blood Group: Binding Properties, Effects on Plasma Levels, and Consequences for Prognostic Performance. | Int J Mol Sci | 2023 |
| 36899057 | A Kinase Interacting Protein 1 (AKIP1) promotes cardiomyocyte elongation and physiological cardiac remodelling. | | 2023 |
| 36765688 | Multifactorial Diseases of the Heart, Kidneys, Lungs, and Liver and Incident Cancer: Epidemiology and Shared Mechanisms. | | 2023 |
| 37079251 | Risk Factors for Immune Checkpoint Inhibitor-Mediated Cardiovascular Toxicities. | | 2023 |
| 37019514 | Association of Initial and Longitudinal Changes in C-reactive Protein With the Risk of Cardiovascular Disease, Cancer, and Mortality. | Mayo Clin Proc | 2023 |
| 36889870 | Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction. | J Am Coll Cardiol | 2023 |
| 36883593 | Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure. | Cardiovasc Res | 2023 |
| 36638956 | Multiple Prior Live Births Are Associated With Cardiac Remodeling and Heart Failure Risk in Women. | J Card Fail | 2023 |
| 37397084 | Evaluation of Senescence and Its Prevention in Doxorubicin-Induced Cardiotoxicity Using Dynamic Engineered Heart Tissues. | | 2023 |
| 37198662 | Sex-based differences in cardiovascular proteomic profiles and their associations with adverse outcomes in patients with chronic heart failure. | Biol Sex Differ | 2023 |
| 36881399 | Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. | JACC Heart Fail | 2023 |
| 36635707 | Sexual dimorphism in selenium deficiency is associated with metabolic syndrome and prevalence of heart disease. | Cardiovasc Diabetol | 2023 |
| 36493852 | Multi-omics analyses identify molecular signatures with prognostic values in different heart failure aetiologies. | | 2023 |
| 36876483 | Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. | Circulation | 2023 |
| 36811901 | Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. | JAMA Cardiol | 2023 |